Encorafenib

Drug Profile

Encorafenib

Alternative Names: LGX-818; NVP-LGX818; NVP-LGX818-NXA

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Developer Array BioPharma; German Cancer Research Center; Novartis Pharmaceuticals Corporation; University of Heidelberg
  • Class Antineoplastics; Carbamates; Pyrazoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Colorectal cancer; Malignant melanoma
  • Phase II Multiple myeloma; Solid tumours

Most Recent Events

  • 31 May 2017 Encorafenib licensed to Ono Pharmaceutical in Japan and South Korea
  • 08 May 2017 Interim adverse events and efficacy data from part 2 of the phase III COLUMBUS trial in Malignant melanoma released by Array BioPharma
  • 14 Nov 2016 9203218 - Added backdated HE for Special Protocol Assessment, which had been missed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top